Targeted therapy in breast cancer: what's new?

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Breast cancer is a leading cause of death in women, with HER-2 positive metastatic disease posing significant treatment challenges.
• Trastuzumab is an effective targeted therapy for HER-2 positive breast cancer, but resistance remains a major clinical issue.
• Understanding the biological mechanisms of resistance is crucial for developing novel therapeutic strategies.

Purpose of the Study:

• To review newly developed targeted agents for breast cancer treatment.
• To discuss novel therapies aimed at overcoming trastuzumab resistance.
• To explore the potential of these agents in combination with trastuzumab.

Main Methods:

• Literature review of recent advancements in targeted breast cancer therapy.
• Discussion of novel targeted agents including monoclonal antibodies, tyrosine kinase inhibitors, PARP inhibitors, mTOR inhibitors, and sheddase inhibitors.
• Analysis of preclinical and clinical data on the efficacy and resistance mechanisms of these agents.

Main Results:

• Several novel targeted agents, including pertuzumab, lapatinib, olaparib, and rapamycin analogues, have emerged as potential treatments for breast cancer.
• These agents demonstrate activity against HER-2 positive breast cancer and may overcome trastuzumab resistance.
• Many novel drugs show complementary or additive effects when combined with trastuzumab, suggesting synergistic therapeutic potential.

Conclusions:

• Novel targeted therapies offer new avenues for treating advanced breast cancer, particularly in cases of trastuzumab resistance.
• Combination strategies involving trastuzumab and novel agents warrant further investigation to optimize treatment outcomes.
• Continued research into the biological underpinnings of breast cancer and targeted therapy is essential for advancing clinical practice.